Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IMPT-314 |
Synonyms | |
Therapy Description |
IMPT-314 comprises autologous naive/memory-enriched T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and CD20 and containing a TNFRSF9 (4-1BB) co-stimulatory domain, which may induce antitumor activity (Blood (2023) 142 (Supplement 1): 6892). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IMPT-314 | IMPT 314|IMPT314 | CD19 Immune Cell Therapy 62 CD20 Immune Cell Therapy 11 | IMPT-314 comprises autologous naive/memory-enriched T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and CD20 and containing a TNFRSF9 (4-1BB) co-stimulatory domain, which may induce antitumor activity (Blood (2023) 142 (Supplement 1): 6892). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05826535 | Phase Ib/II | IMPT-314 | Study of IMPT-314 in R/R Aggressive B-cell | Recruiting | USA | 0 |